Delayed edition for Thursday, November 19, 2026.Celldex says it is ending barzolvolimab development in atopic dermatitis after its Phase 2 trial missed the primary itch endpoint. Revolution Medicines reports single-arm data for Rasonque (daraxonrasib) plus chemotherapy in first-line metastatic pancreatic cancer; a separate randomized study is designed to show what the drug adds. The roundup covers Pyxis Oncology’s Phase 1 micvotabart pelidotin data in head and neck cancer, the AbbVie–DISCO oncology discovery deal and Recursion’s proposed REC-4881 trial in familial adenomatous polyposis. Johnson & Johnson files to expand Caplyta (lumateperone) to manic or mixed episodes in bipolar I disorder, Novartis raises three peak sales forecasts, and a US biotech commission assesses China’s pharma competitiveness.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →